Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 2/20 | 0.65 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.56 |
| ▸ | CTSB | P07858 | 3/20 | 0.54 |
| ▸ | TACR1 | P25103 | 3/20 | 0.52 |
| ▸ | CTSL | P07711 | 5/20 | 0.51 |
| ▸ | CTSK | P43235 | 4/20 | 0.51 |
| ▸ | CTSS | P25774 | 4/20 | 0.51 |
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | PLAT | P00750 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9015424 | 0.93 | CTRB1 (0.57) | CTRB1TRPM8CTSBTACR1CTSL | |
| SCHEMBL7303656 | 0.93 | CTRB1 (0.57) | CTRB1TRPM8CTSBTACR1CTSL | |
| SCHEMBL15159955 | 0.91 | KLK5 (0.59) | CTRB1TRPM8CTSBCTSLCTSK | |
| SCHEMBL16283136 | 0.91 | KLK5 (0.59) | CTRB1TRPM8CTSBCTSLCTSK | |
| SCHEMBL7342899 | 0.90 | CTRB1 (0.60) | CTRB1TRPM8CTSBTACR1CTSL | |
| SCHEMBL7303011 | 0.90 | CYP3A4 (0.63) | CTRB1TRPM8CTSBTACR1CTSL | |
| SCHEMBL7569915 | 0.90 | CYP3A4 (0.63) | CTRB1TRPM8CTSBTACR1CTSL | |
| SCHEMBL7305488 | 0.90 | CYP3A4 (0.63) | CTRB1TRPM8CTSBTACR1CTSL | |
| SCHEMBL7298831 | 0.90 | CTRB1 (0.53) | CTRB1TRPM8CTSBTACR1CTSL | |
| SCHEMBL7301720 | 0.89 | CTRB1 (0.52) | CTRB1TRPM8CTSBTACR1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1302468-B1 | Processes and intermediates for manufacturing retroviral protease inhibiting compounds | ABBOTT LAB (US) | 2008-12-17 | — | — | EP | disclosed |
| US-6667404-B2 | Carbamylation of 1-amino group of 1,4-amino-3-hydroxybutane derivative with an organocarbonate containing thiazolyl, oxazolyl, isoxazolyl or isothiazolyl substituent | ABBOTT LABORATORIES | 2003-12-23 | — | — | US | disclosed |
| US-20030195362-A1 | Retroviral protease inhibiting compounds | KEMPF DALE J (US) | 2003-10-16 | — | — | US | disclosed |
| EP-1302468-A1 | Processes and intermediates for manufacturing retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2003-04-16 | — | — | EP | disclosed |
| US-6531610-B1 | Intermediate acylating carbonate | ABBOTT LABORATORIES | 2003-03-11 | — | — | US | disclosed |
| EP-1090914-B1 | Retroviral protease inhibiting compounds | ABBOTT LAB (US) | 2003-01-02 | — | — | EP | disclosed |
| EP-0727419-B1 | Intermediates for the preparation of retroviral protease inhibiting compounds | ABBOTT LAB (US) | 2002-02-27 | — | — | EP | disclosed |
| EP-0732923-B1 | Pharmaceutical compositions containing HIV protease inhibitors | ABBOTT LAB (US) | 2001-12-12 | — | — | EP | disclosed |
| EP-1090914-A2 | Processes and intermediates for manufacturing retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2001-04-11 | — | — | EP | disclosed |
| US-6150530-A | AMIDATION OF AMINE WITH ACID | ABBOTT LABORATORIES (US) | 2000-11-21 | — | — | US | disclosed |
| US-5559158-A | PROTEASE INHIBITOR ADSORBED ON SILICA, MICROCRYSTALLINE CELLULOSE, IMPROVED BIOAVAILABILITY,TREATMENT OF HIV | ABBOTT LABORATORIES (US) | 1996-09-24 | — | — | US | disclosed |
| US-5554783-A | (2R, 3R, 4S, 5S)-3-ACETOXY-2,5-BIS/BENZYLOXYCARBONYLAMINO/ -4-BROMO-1,5-DIPHENYLHEXANE | ABBOTT LABORATORIES (US) | 1996-09-10 | — | — | US | disclosed |
| US-5552558-A | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1996-09-03 | — | — | US | disclosed |
| EP-0727419-A2 | Retroviral protease inhibiting compounds | Abbott Laboratories (US) | 1996-08-21 | — | — | EP | disclosed |
| US-5541334-A | TREATING HIV | ABBOTT LABORATORIES (US) | 1996-07-30 | — | — | US | disclosed |
| US-5541206-A | TREATING HUMAN IMMUNODEFICIENCY VIRUS INFECTION | ABBOTT LABORATORIES (US) | 1996-07-30 | — | — | US | disclosed |
| US-5539122-A | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1996-07-23 | — | — | US | disclosed |
| US-5484801-A | Pharmaceutical composition for inhibiting HIV protease | ABBOTT LABORATORIES (US) | 1996-01-16 | — | — | US | disclosed |
| US-5354866-A | Treating HIV infections | ABBOTT LABORATORIES (US) | 1994-10-11 | — | — | US | disclosed |
| EP-0486948-A2 | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1992-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195362-A1 | Retroviral protease inhibiting compounds | PREP, SERPINB1, PRSS1 | CTRB1 172/4885TRPM8 4395/4885CTSB 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.